GeneLink (GNLKQ) 10-K/A 17 Dec 13 2012 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2012	Mar. 20, 2013	Jun. 30, 2012
Entity Registrant Name	'GENELINK INC	'	'
Entity Central Index Key	'0000941020	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'gnlk	'	'
Entity Common Stock, Shares Outstanding	'	253,352,022	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-12	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2012	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$4,102,214

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2012	Dec. 31, 2011
ASSETS	'	'
Cash and cash equivalents	$158,468	$740,769
Accounts Receivable, net	77,966	235,458
Inventory	393,588	562,191
Prepaid Expenses	50,258	244,248
Current portion of Prepaid Sales Incentive	92,000	76,667
Total Current Assets	772,280	1,859,333
Property and Equipment	257,769	167,812
Prepaid Sales Incentives	291,330	383,333
Intangible Assets	54,905	235,587
Loan Costs, net of accumulated amortization of $154,100 and $108,544	58,703	104,257
Other Assets	19,814	29,343
Total Assets	1,454,801	2,779,665
LIABILITIES AND SHAREHOLDERS EQUITY	'	'
Accounts payable	1,019,372	1,370,849
Accrued interest	463,815	304,457
Accrued compensation	34,698	94,188
Other accrued expenses	139,827	103,370
Deferred revenue	21,352	208,279
Advances from purchaser of subsidiary	0	204,500
Current portion of deferred revenue-license fees	150,000	0
Due to shareholder	10,000	10,000
Total current liabilities	1,839,064	2,295,643
Non-refundable advance deposit for licensing agreement	725,043	750,000
Deferred revenue - license fees	462,500	250,000
Convertible notes payable, net of discounts - related parties	1,089,547	965,015
Total Liabilities	4,116,154	4,260,658
STOCKHOLDERS' DEFICIT	'	'
Common stock, par value $0.01 per share; authorized 350,000,000 shares; issued: 257,711,181 and 204,944,485 shares; outstanding: 253,352,022 and 200,585,326 shares	2,577,112	2,049,448
Additional paid in capital	22,925,832	21,582,109
Accumulated deficit	-27,612,062	-24,560,315
Treasury stock, 4,359,159 shares, at cost	-552,235	-552,235
Total stockholders' deficit	-2,661,353	-1,480,993
Total liabilities and stockholders' deficit	$1,454,801	$2,779,665

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS Parenthetical (USD $)	Dec. 31, 2012	Dec. 31, 2011
Accumulated amortization, loan costs (in dollars)	$154,100	$108,544
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	257,711,181	204,944,485
Common stock, shares outstanding	253,352,022	200,585,326
Treasury stock, shares	4,359,159	4,359,159

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Revenues	$2,136,142	$4,684,577
Cost of goods sold	1,671,459	1,734,831
Gross profit	464,683	2,949,746
Operating Expenses:	'	'
Selling, general and administrative	3,442,362	6,247,084
Research and development	250,808	134,500
Depreciation and amortization	174,993	134,777
Loss on abandonment of patents	65,517	0
Operating Expenses	3,933,680	6,516,361
OPERATING LOSS	-3,468,997	-3,566,615
OTHER INCOME (EXPENSE)	'	'
Gain on sale of subsidiary	669,054	0
Gain on settlement of lawsuit	77,742	0
Interest expense	-331,085	-265,814
Interest income	1,539	2,233
Nonoperating Income (Expense)	417,250	-263,581
NET LOSS	($3,051,747)	($3,830,196)
Loss per common share - basic and diluted (in dollars per share)	($0.01)	($0.02)
Weighted average common shares - basic and diluted (in shares)	214,447,037	180,567,494

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Deficit (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2010	$1,553,735	$18,938,762	($20,730,119)	($552,235)	($789,857)
Balance (in shares) at Dec. 31, 2010	155,373,185	'	'	'	'
Issuance of common stock pursuant to private placement offerings, net of offering costs	487,700	1,811,620	0	0	2,299,320
Issuance of common stock pursuant to private placement offerings, net of offering costs (in shares)	48,770,000	'	'	'	'
Exercise of stock options and warrants	5,013	-4,943	0	0	70
Exercise of stock options and warrants (in shares)	501,300	'	'	'	'
Stock-based compensation	0	356,925	0	0	356,925
Issuance of common stock for services	3,000	19,745	0	0	22,745
Issuance of common stock for services (in shares)	300,000	'	'	'	'
Issuance of stock warrants for license and distribution agreement	0	460,000	0	0	460,000
Net loss	0	0	-3,830,196	0	-3,830,196
Balance at Dec. 31, 2011	2,049,448	21,582,109	-24,560,315	-552,235	-1,480,993
Balance (in shares) at Dec. 31, 2011	204,944,485	'	'	'	'
Issuance of common stock pursuant to private placement offerings, net of offering costs	525,000	979,000	0	0	1,504,000
Issuance of common stock pursuant to private placement offerings, net of offering costs (in shares)	52,500,000	'	'	'	'
Exercise of stock options and warrants	282	-282	0	0	0
Exercise of stock options and warrants (in shares)	28,160	'	'	'	'
Stock-based compensation	0	292,525	0	0	292,525
Issuance of common stock for services	14,973	59,889	0	0	74,862
Issuance of common stock for services (in shares)	1,497,226	'	'	'	'
Other adjustments	-12,591	12,591	0	0	0
Other adjustments (in shares)	-1,258,690	'	'	'	'
Net loss	0	0	-3,051,747	0	-3,051,747
Balance at Dec. 31, 2012	$2,577,112	$22,925,832	($27,612,062)	($552,235)	($2,661,353)
Balance (in shares) at Dec. 31, 2012	257,711,181	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($3,051,747)	($3,830,196)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	174,993	134,777
Depreciation included in cost of goods sold	38,003	0
Amortization of debt discounts	124,533	113,649
Amortization of loan origination costs	45,554	41,565
Common stock issued for services	74,862	22,745
Gain on sale of subsidiary	-669,054	0
Gain on settlement of lawsuit	-77,742	0
Loss on abandonment of patents	65,517	0
Amortization of prepaid sales incentives	76,670	'
Amortization of customer deposit	-24,957	'
Amortization of deferred license fees	-137,500	'
Stock-based compensation	292,525	356,925
Changes in assets and liabilities:	'	'
Accounts receivable	-74,789	70,166
Inventory	170,770	-338,495
Prepaid expenses	128,836	-157,693
Other assets	9,536	4,100
Accounts payable and accrued expenses	34,345	492,404
Accrued compensation	-3,781	-113,652
Deferred revenue	-80,181	52,612
Deferred revenues - license fees	500,000	250,000
Net cash used in operating activities	-2,383,607	-2,901,093
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Capital expenditures	-241,966	-41,327
Proceeds from sale of subsidiary, net of cash transferred	539,272	0
Long-term receivable related to sale of subsidiary, net	-164,358	0
Collections on receivable from sale of subsidiary	164,358	0
Net cash provided (used) in investing activities	297,306	-41,327
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from advances from purchaser	0	204,500
Proceeds from issuance of common stock and warrants, net	1,504,000	2,299,320
Proceeds from exercise of stock options	0	70
Proceeds from non-refundable advance deposit	0	750,000
Net cash provided by financing activities	1,504,000	3,253,890
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-582,301	311,470
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	740,769	429,299
CASH AND CASH EQUIVALENTS, END OF PERIOD	158,468	740,769
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION	'	'
Cash payments for interest	1,642	4,752
Conversion of accrued consulting fees to common stock	0	90,000
Issuance of warrants in exchange for prepaid sales incentives	$0	$460,000

Organization

Organization	12 Months Ended
	Dec. 31, 2012
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1.	Organization
	The Company is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies that can have a significant impact on overall wellness of an individual client or customer.  These small differences in DNA, called SNP’s (“snips”) can indicate genetic variants that may not be performing at optimal levels and can be linked to aging and other wellness issues. GeneLink scientists use the DNA assessments information on each client and then formulate products to optimize health and wellness within the normal ranges.  As discussed further in Note 11, the Company divested its interest in its wholly-owned subsidiary, GeneWize Life Sciences, Inc. (“GeneWize”), effective February 10, 2012 as part of a strategic realignment of its business to offer its products through third-party market partners, and to refocus efforts on research, development and manufacturing of custom products for those market partners.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2012
Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	Note 2.	Summary of Significant Accounting Policies
	Principles of consolidation:
	The consolidated financial statements include the accounts of GeneLink, Inc. and its wholly-owned Subsidiaries.  All significant intercompany accounts and transactions have been eliminated in the consolidation.
	Use of estimates:
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	Cash and cash equivalents:
	Highly liquid instruments purchased with a maturity of three months or less are considered to be cash equivalents.  At times, cash and cash equivalents may exceed federally insured limits.  The Company has not experienced any losses on such accounts. All non-interest bearing cash balances were fully insured at December 31, 2012 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the Company's non-interest bearing cash balances may again exceed federally insured limits. The Company had $381,277 of interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2011 and no excess of interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2012.
	Accounts Receivable:
	Trade accounts receivable primarily represent amounts due from distributors of our products.  The company performs credit evaluations of each customer on an ongoing basis and generally does not require collateral or charge interest or fees on balances.  As of December 31, 2012 and 2011, the Company has not recorded an allowance for doubtful accounts as management determined all amounts are collectible.
	Inventory:
	Inventory is valued at the lower of cost (using the first-in, first-out method) or market.  Inventory consists primarily of raw materials for the custom nutritional and skincare products sold by the Company.  Cost is determined on a specific identification basis. Work in process  and finished goods inventory are insignificant in relation to the raw material inventory since production process is short and goods are manufactured to order and shipped shortly after completion.  The cost of finished goods inventory includes the cost of materials, third-party contract manufacturing and overhead. In the event that the Company identifies excess, obsolete or unsalable inventory, its value is
	written down to net realizable value.
	Property and equipment:
	Property and equipment are stated at cost.  Expenditures for maintenance and repairs are charged against operations.  Renewals and betterments that materially extend the life of the assets are capitalized.  Depreciation is computed using the straight-line method over the estimated useful lives or the lesser of the expected life or term of the lease as to leasehold improvements as noted below:
	Office furniture and equipment	3 - 5 years
	Equipment	3 - 5 years
	Leasehold improvements	5 years
	Software	3 - 5 years
	Intangible Assets:
	Intangible assets include costs incurred to apply and obtain patents for its products. Patents are amortized upon approval by regulatory authorities over the estimated useful life of the asset, generally fifteen years on a straight-line basis.
	Deferred Loan Costs:
	Loan acquisition costs are amortized over the term of the debt using the effective interest method.
	Long lived assets:
	The Company reviews its long-lived assets and certain identifiable intangibles for impairment whenever events or changes indicate that the carrying amount of an asset may not be recoverable.  An impairment loss would be recognized when estimated future cash flows expected to result from the use of an asset and its eventual disposition is less than its carrying amount.  The Company recorded $65,517 of impairment loss from abandonment of patents in the year ended December 31, 2012 and had not identified any such impairment losses during the year ended December 31, 2011.
	Revenue recognition:
	The Company recognizes revenues from the sales of products upon shipment.  Revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred and title and risk of loss have transferred to the customer, the sales price is determinable and collectability is reasonably assured.
	For direct sales to consumers by the Company’s subsidiary, GeneWize, prior to its sale in 2012, revenue was reduced for refunds on certain products during the trial period which is the first 60 days after the initial order is shipped. The Company recorded a reserve for refunds based on historical refunds provided to customers which is recorded as a reduction of revenue and is included in accrued expenses on the accompanying balance sheet.   The Company received advance payments from these consumer sales which was recorded as deferred revenue until shipment occurs.
	Prepaid sales incentives and deferred revenue-license fees represent prepaid fees that are deferred and recognized over the term of the underlying agreement with licensees.
	The Company recognizes revenue from licensing agreements as earned, which is generally when products are shipped from distributors, over the term of the agreement.
	Research and Development:
	Research and development costs are expensed as incurred.
	Advertising
	The Company expenses advertising when incurred.  Advertising expense was $28,924 and $57,825 for the years ended December 31, 2012 and 2011, respectively.
	Stock-Based Compensation:
	Stock-based compensation is recorded for recognition of the cost of employee or director services received in exchange for an award of equity instruments in the financial statements and is measured based on the grant date fair value of the award.  The stock-based compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (typically, the vesting period).
	The Company estimates the fair value of each option award issued under its stock option plans on the date of grant using a lattice option-pricing model that uses the following assumptions:
		a)	The Company estimates the volatility of its common stock at the date of grant based on the historical volatility of its common stock for a period commensurate with the expected life. These historical periods may exclude portions of time when unusual transactions occurred.
		b)	The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures.
		c)	For shares that vest contingent upon achievement of certain performance criteria, an estimate of the probability of achievement is applied in the estimate of fair value. If the goals are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed.
		d)	The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future.
		e)	The risk-free interest rate is based upon a treasury security with a maturity comparable to the contractual term of the options.
	In addition, the Company separates the grants into homogeneous groups and analyzes the assumptions for each group and computes the expense for each group utilizing these assumptions.
			Assumptions for Awards Granted in
			Years Ended December 31,
			2012			2011
	Expected volatility			180-182	%		144-203	%
	Risk-free interest rate			4.5	%		4.5-5.0	%
	Expected dividend yield			0	%		0	%
	Expected life in years			5.0-10.0			5.0 – 10.0
	Earnings per share:
	Basic loss per share is calculated using the weighted average number of common shares outstanding for the period and diluted is computed using the weighted average number of common shares and dilutive common equivalent shares outstanding.  Given that the Company is in a net loss position, there is no difference between basic and diluted weighted average shares since the common stock equivalents would be antidilutive.
	The following common stock equivalents are excluded from the loss per share calculation as their effect would have been antidilutive:
			Year Ended December 31,
			2012			2011
	Options			21,980,833			19,631,833
	Warrants			24,248,042			22,552,458
	Debt conversion shares			16,794,583			15,544,583
	Debt conversion warrants			1,875,000			1,875,000
	Income taxes:
	The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.
	The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2008 through December 31, 2012.
	Derivative Financial Instruments:
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and equity instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required to be accounted for separately from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results. An evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.
Beneficial Conversion and Warrant Valuation:
The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt instruments that have conversion features at fixed rates that are in-the-money when issued.  The Company also records the fair value of warrants issued in connection with debt instruments. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds to warrants, based on their relative fair value, and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion feature. The discounts recorded in connection with the BCF and warrant valuation are recognized for convertible debt as interest expense over the term of the debt using the effective interest method.
Fair Value of Financial Instruments:
The Company’s financial instruments are recorded at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:
	·	Level 1 – Valuation based on quoted market prices in active markets for identical assets and liabilities.
	·	Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.
	·	Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.
Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2012. The Company uses the market approach to measure fair value of its Level 1 financial assets.  The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s convertible notes payable approximate their carrying value based upon current rates available to the Company.
In 2009, the Company issued Convertible Notes and warrants to a group of accredited investors (see Note 8). The Company engaged a third party to complete a valuation of the warrants issued to the placement agent and note holders and the conversion feature under the Convertible Notes which are recorded as debt costs and debt discounts on the accompanying balance sheets. The valuation was completed using Level 2 inputs.
During 2011, the Company issued warrants in connection with a license and distribution agreement (see Note 11) and engaged a third party to complete a valuation of those warrants which were recorded as Prepaid Sales Incentive on the accompanying balance sheet. The valuation was completed using Level 2 inputs.
Industry Risk and Concentration:
The business of marketing nutrition and skin care products is highly competitive and sensitive to the introduction of new products which may rapidly capture a significant share of the market. These market segments include numerous manufacturers, distributors, marketers, retailers and physicians that actively compete for the business of consumers both in the United States and abroad. In addition, the Company anticipates that it will be subject to increasing competition in the future from sellers that utilize electronic commerce. Many of these competitors have longer operating histories, significantly greater financial, technical, product development, marketing and sales resources, greater name recognition, larger established customer bases and better-developed distribution channels than does the Company.
The Company’s present or future competitors may be able to develop products that are comparable or superior to those offered by the Company, adapt more quickly than the Company does to new technologies, evolving industry trends and standards or customer requirements, or devote greater resources to the development, promotion and sale of their products than does the Company. For example, if the Company’s competitors develop skin care or nutritional treatments that prove to be more effective than our products, demand for our products could be reduced. Accordingly, the Company may not be able to compete effectively in our markets and competition may intensify.  The Company is also subject to significant competition for the recruitment of distributors from other network marketing organizations, including those that market nutritional supplements and skin care products as well as other types of products.
The Company’s ability to be competitive will depend, in significant part, on its success in recruiting and retaining market partners through the maintenance of an attractive product portfolio and other incentives. The Company cannot ensure that its programs for recruitment and retention of partners  will be successful, and if they are not, the Company’s financial condition and operating results would be harmed.
The Company sells its products through a limited number of distributors. Certain of these distributors, together with entities under their common control, each individually accounted for greater than 10% of total revenues and greater than 10% of accounts receivable as follows: Revenues for 2012 and accounts receivable as of December 31, 2012 from GeneWize, our former subsidiary were $1,476,000 and $77,811, respectively which accounted for 69% of our net sales for the year and 100% of our outstanding accounts receivable at year end. No other customers were more than 10% of sales and revenues generated outside the United States were less than 10% of total revenues for all years presented.
The Company relies entirely on a limited number of third parties to supply raw materials, manufacture our products and perform laboratory tests on the Company’s behalf. In the event any of the Company’s third party suppliers, manufacturers or laboratories was to become unable or unwilling to continue to provide the Company with services and products in required volumes and at suitable quality levels, the Company would be required to identify and obtain acceptable replacement sources.
Recent accounting pronouncements
In July 2012, the Financial Accounting Standards Board completed an accounting standards update entitled "ASU 2012-02, Intangibles - Goodwill and Other" that revises the requirements around how entities test indefinite-lived intangible assets, other than goodwill, for impairment. The guidance will allow entities to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. If entities determine, on the basis of qualitative factors, that the fair value of the indefinite-lived intangible asset is more likely than not greater than the carrying amount, a quantitative calculation would not be needed. The Company will adopt this standard in the first quarter of 2013 and does not expect the adoption of this standard to have an impact on its consolidated financial statements.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 3.	Property and Equipment
	Property and equipment consisted of the following:
			December 31,
			2012			2011
	Office furniture and equipment		$	4,135		$	85,651
	Machinery  & equipment			288,105			301,091
	Leasehold improvements			169,629			6,781
	Software			21,946			343,902
	Less accumulated depreciation			(226,046	)		(569,613	)
			$	257,769		$	167,812
	Depreciation expense was $98,258 and $129,707 for the years ended December 31, 2012 and 2011, respectively.  For the year ended December 31, 2012, $38,003 of depreciation was included in cost of goods sold.  No depreciation expense was included in cost of goods sold for the year ended December 31, 2011 as manufacturing operations were contracted to a third party vendor.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 4.	Intangible Assets
	Intangible assets consisted of the following:
			December 31,
			2012			2011
	Patents approved		$	77,574		$	70,556
	Patents pending			115,237			188,298
	Less accumulated amortization			(137,906	)		(23,267	)
			$	54,905		$	235,587
	Amortization expense related to patents was $114,738 and $5,070 for the years ended December 31, 2012 and 2011, respectively. 2012 amortization expense includes a charge of $106,000 related to accelerated amortization as a result in the change of estimated useful lives of certain patents.  In addition, $65,517 in patent costs were written off in the year ended December 31, 2012 due to impairment of their estimated future value.
	The future estimated amortization expense on patents and other intangible assets that will be charged to operations as of December 31, 2012 is as follows:
	Year ending
	December 31,
	2013		$	11,901
	2014			9,190
	2015			8,235
	2016			7,697
	2017			2,758
	Thereafter			15,124
			$	54,905

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 5.	Income Taxes
	Because of the Company's history of net operating losses, it has not paid income taxes since its inception and the Company had no material unrecognized tax benefits that could affect the Company's financial statements as of December 31, 2012 or 2011.  The Company's deferred tax assets primarily consist of net operating loss, or NOL, carryforwards, stock compensation items and deferred revenue. Realization of deferred tax assets is dependent upon a number of
	factors, including future earnings
	Components of deferred tax assets (liabilities) are as follows:
			December 31,
			2012			2011
	Stock compensation		$	856,000		$	713,900
	Other components			148,000			137,200
	Net operating loss carryforwards			6,778,000			7,826,700
				7,782,000			8,677,800
	Valuation Allowance			(7,782,000	)		( 8,677,800	)
			$	-		$	-
	The reconciliation of income tax attributable to operations computed at the United States federal statutory rate and the actual tax provision of zero results primarily from the change in the valuation allowance.
	As of December 31, 2012, the Company had net operating loss carry forwards for federal and state income tax purposes of approximately $17,958,000 which expire in various amounts between 2014 and 2031. A portion of the net operating loss carryforwards may be subject to certain limitations of the Internal Revenue Code section 382 which would restrict the annual utilization in future periods due to changes in ownership in prior periods.  The Company has evaluated its ability to realize the deferred tax assets on its balance sheet and has established a valuation allowance at December 31, 2011and 2012.  The valuation allowance decreased by $895,800 during 2012 due to the sale of GeneWize and its related tax loss carryforward.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 6.	Stockholders' Equity
	Common Stock
	During 2012, the Company sold an aggregate of 52,500,000 of shares of Common Stock in private placement offerings, at a price of $0.03 per share for net proceeds of $1,504,000.  Costs incurred in the offerings were $71,000. The Company issued warrants to purchase 5,041,667 shares of Common Stock at an exercise price of $0.03 per share to First Equity Capital Securities, Inc., as placement agent.  Kenneth R. Levine, a holder of more than five percent of the equity securities of the Company, is an officer and owner of First Equity Capital Securities, Inc. and a member of the Scientific Advisory Board.
	During 2012, 400,000 warrants were issued as partner incentives to Joel Guerin in connection with the Company’s distribution agreement with geneME.
	During 2011, the Company sold an aggregate of 48,770,000 of shares of Common Stock in private placement offerings, at a price of $0.05 per share for net proceeds of $2,299,320. Costs incurred in the offerings were $139,180. The Company issued warrants to purchase 3,104,500 shares of Common Stock at an exercise price of $0.05 per share to First Equity Capital Securities, Inc., as placement agent.  Kenneth R. Levine, a holder of more than five percent of the equity securities of the Company, is an officer and owner of First Equity Capital Securities, Inc. and a member of the Scientific Advisory Board.
	As discussed in Note 11, during 2011 the Company issued 8,000,000 non-performance warrants in connection with the license and distribution agreement.
	The Company issued 1,497,226 shares of common stock for services rendered during the year ended December 31, 2012. The fair value per share was based upon market transactions in our stock and was determined to be $.05 per share which resulted in an expense charge of ,$74,862  in aggregate.
	The Company issued 300,000 shares of common stock for services rendered, valued at $22,745 or $0.075  per share on November 1, 2011 which was the only grant for services for the year ended December 31, 2011. The fair value per share was based upon market transactions in our stock.
	Warrants
	Warrants outstanding as of December 31, 2012 are as follows:
	Warrant Description		Shares			Exercise		Expiration
						Price		Date
	Placement Agent  Fees			12,490,542		$	0.03-$0.15		2013-2017
	Partner performance warrants			400,000		$	0.05		2017
	License fees			8,000,000		$	0.10-$0.45		2016
	Private  Placement warrants			3,357,500		$	0.10-$0.15		2013-2016
	Total warrants			24,248,042
	The following table summarizes the activity of the stock warrants outstanding for the years ended December 31, 2011 and 2012:
			Shares Under
			Warrant
	Balance, January 1, 2011			13,087,958
	Warrants Issued			11,104,500
	Warrants Exercised			(1,640,000	)
	Warrants Expired			-
	Balance, December 31, 2011			22,552,458
	Warrants Issued			5,441,667
	Warrants Exercised			(100,000	)
	Warrants Expired			(3,646,083	)
	Balance, December 31, 2012			24,248,042
	During 2012, 100,000 warrants were exercised for 28,160 common shares.
	Stock Option Plans
	In 2007, the Company adopted a stock options plan (the “2007 Plan”) that provides for the grant of incentive stock options and nonqualified stock options, and reserved 6,000,000 shares of the Company’s Common Stock for future issuance under the 2007 Plan.  The option price must be at least 100% of market value at the date of the grant and the options have a maximum term of 10 years.  Options granted vest over varying terms at the discretion of the Board.  The Company typically grants selected key employees, Board members and consultants to the Company awards.  As of December 31, 2012, options to purchase 5,050,000 shares of common stock were vested and exercisable under the 2007 Plan.
	On June 1, 2009, the Company adopted a  stock option plan (the “2009 Plan”) that provides for the grant of incentive stock options and nonqualified stock options, and reserved 6,000,000 shares of the Company’s Common Stock for future issuance under the 2009 Plan.  The option price must be at least 100% of market value at the date of the grant and the options have a maximum term of 10 years.  Options granted vest over varying terms at the discretion of the Board.  The Company typically grants stock options  to selected key employees, Board members and consultants to the Company.  As of December 31, 2012, options to purchase 3,906,250 shares of common stock were vested and exercisable under the 2009 Plan.
	On May 20, 2011, the Company adopted a stock option plan (the “2011 Plan”) that provides for the grant of incentive stock options and nonqualified stock options, and reserved 10,000,000 shares of the Company’s Common Stock for future issuance under the 2011 Plan.  The option price must be at least 100% of market value at the date of the grant and the options have a maximum term of 10 years.  Options granted vest at the discretion of the Board, typically over a three year period or based on achievement of performance criteria.  The Company typically grants stock options to selected key employees, Board members and consultants to the Company.  As of December 31, 2012, options to purchase 2,674,375 shares of common stock were vested and exercisable under the 2011 Plan.
	In addition, the Board has, from time to time granted stock options outside of the above named plans (“Board-designated options”).  At December 31, 2012 and December 31, 2011, 4,945,833 shares were outstanding under Board-designated options.   As of December 31, 2012, options to purchase 4,350,000 shares of common stock were vested and exercisable under the Board-designated options.
	The average fair value of options granted at market during 2012 and 2011 was $0.04 and $0.09 per option, respectively. The aggregate intrinsic value of the outstanding options at December 31, 2012 was $0.
	The following table summarizes activity of the stock options outstanding for the years ended December 31, 2012 and 2011:
			Shares Under			Weighted
			Option			Average
						Exercise Price
	Balance,  January 1, 2011			15,682,833		$	0.13
	Options granted at market			4,900,000			0.09
	Options exercised			(1,000	)		0.07
	Options forfeited or expired			(950,000	)		0.08
	Balance, December 31, 2011			19,631,833			0.12
	Options granted at market			3,060,000			0.04
	Options forfeited or expired			(711,000	)		0.08
	Balance, December 31, 2012			21,980,833		$	0.11
	Of the 21,980,833 options outstanding at December 31, 2012, 15,980,625 are vested and exercisable. At December 31, 2012, the weighted average exercise price of vested options outstanding was $0.11, the weighted average remaining contractual term (in years) was 6.44 and the aggregate intrinsic value was $0.
	A summary of the non-vested shares as of December 31, 2012 and changes during the year ending December 31, 2012 and 2011 is presented below:
			Non-Vested Shares			Weighted Average Grant-Date Fair Value
	Non-vested at January 1, 2011			5,820,333		$	0.19
	Granted			4,900,000			0.08
	Vested			(3,412,000	)		0.16
	Non-vested at January 1, 2012			7,308,333		$	0.14
	Granted			3,060,000			0.04
	Vested			(4,118,125	)		0.07
	Cancelled			(250,000	)		0.08
	Non-vested at December 31, 2012			6,000,208		$	0.07
	As of December 31, 2012, the total future compensation cost related to non-vested awards expected to vest is estimated to be approximately $234,200, $126,200 and $52,950 for the years ending December 31, 2013, 2014, and 2015 respectively.
	The total fair value of shares vested during the years ended December 31, 2012 and 2011 was approximately $292,525 and $356,925, respectively.
	No tax benefit was recognized related to share-based compensation expense since the Company has never reported taxable income and has established a full valuation allowance to offset all of the potential tax benefits associated with its deferred tax assets.

Leases

Leases	12 Months Ended
	Dec. 31, 2012
Leases [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	Note 7.	Leases
	The Company leases its office space and manufacturing facility under various operating leases which have terms expiring on various dates from 2013 through 2017.
	Future minimum lease payments with terms in excess of one year as of December 31, 2012 are as follows:
	Year ending
	December 31,
	2013		$	202,404
	2014			208,476
	2015			214,730
	2016			221,172
	2017			93,287
			$	940,069
	Rent expense during the years ended December 31, 2012 and 2011 was approximately $135,680 and $64,900, respectively.

Convertible_Notes_Payable_Rela

Convertible Notes Payable - Related Parties	12 Months Ended
	Dec. 31, 2012
Convertible Notes Payable Related Parties [Abstract]	'
Convertible Notes Payable Related Parties [Text Block]	'
	Note 8.	Convertible Notes Payable – Related Parties
	In February 2009, the Company entered into Convertible Note agreements (the “Convertible Notes”) with a limited number of accredited investors who are shareholders of the company. Pursuant to the Convertible Notes, the Company sold an aggregate of $1,250,000 in principal and 1,875,000 warrants (the “2009 Note Warrants”) to purchase shares of the Company’s common stock. The Convertible Notes are payable in full on February 26, 2014 and incurred simple interest, payable monthly, at the rate of 8.0% per year through February 26, 2011, and thereafter incur simple interest at the rate of 10.0% per year through maturity. The Convertible Notes may only be prepaid upon approval of the holders and are convertible at the option of the holders. A mandatory conversion of the Convertible Notes will occur if the closing price of the Company’s Common Stock is at least $0.50 per share for 30 consecutive trading days. The conversion price on the Convertible Notes is $0.10 per share, subject to adjustment under standard anti-dilution provisions, as defined in the agreements.
	The 2009 Note Warrants are exercisable at any time at an exercise price of $0.11 per share and expire on February 26, 2014. The 2009 Note Warrants become immediately exercisable upon the occurrence of a Change in Control Event, as defined in the warrant agreement. The 2009 Note Warrants contain a cashless exercise provision.
	Using a simulation model of discounted cash flows, the relative fair value of the Convertible Notes was calculated to be $1,328,325. The fair value of the 2009 Note Warrants was calculated to be $204,750. The fair value of the 2009 Note Warrants was calculated using binomial lattice valuation model with the following assumptions: Expected life in years: 5; Estimated volatility: 138% - 163%; Risk-free interest rate: 4.98%; Dividend yield: 0%.
	The proceeds from the Convertible Notes have been discounted for the relative fair value of the 2009 Note Warrants of $166,395, which was recorded as additional paid-in capital. The warrant discount is being amortized over the life of the Convertible Notes using the effective interest method. For the years ended December 31, 2011 and 2012, $34,248 and $37,536 of the warrant discount was amortized to interest expense, respectively. The total fair value allocated to the Convertible Notes was $1,083,605, of which $406,395 was allocated to a beneficial conversion feature (“BCF”) and was recorded in additional paid-in capital. A BCF is recorded as a debt discount when the consideration allocated to the convertible security, divided by the number of common shares into which the security converts, is below the fair value of the common stock at the date of issuance of the convertible instruments. The BCF is being amortized to interest expense over the life of the Convertible Notes using the effective interest method. Amortization of the BCF amounted to $79,379 and $86,997 during the years ended December 31, 2011 and 2012, respectively.
	The Company paid $80,000 cash to the placement agent in conjunction with the Convertible Notes issuance. The placement agent also received 1,265,000 warrants at an exercise price of $.11 per share as additional compensation. The fair value of the warrants issued to the placement agent totaled $132,800, the value of which, along with the $80,000 in cash, was recorded by the Company as debt issuance costs. The debt issuance costs are being amortized over the life of the Convertible Notes using the effective interest method. For the years ended December 31, 2011 and 2012, $41,565 and $45,554 of the debt issuance costs was amortized to interest expense. The remaining unamortized debt issuance costs balance was $104,256 and $58,703 for the years ended December 31, 2011 and 2012, respectively.
	The total principal balance outstanding on the 2009 Notes was $1,250,000 at both December 31, 2011 and 2012. The total unamortized discounts resulting from the warrant and BCF were $284,985 and $160,453 at December 31, 2011 and 2012, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2012
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 9.	Related Party Transactions
	Placement Agent Fees
	As discussed in Note 6, in connection with private placement offerings of its common stock during 2012 and 2011, the Company paid its placement agent, a company owned by a more than 5% stockholder and officer of the Company, $71,000 and $78,720, respectively.  In addition, during 2011 this placement agent was issued warrants to purchase 3,104,500 shares of Common Stock at an exercise price of $0.05 per share and during 2012 warrants to purchase 5,041,667 shares of Common Stock at an exercise price of $0.03 per share.
	Consulting Fees
	The Company entered into a consulting agreement with a shareholder and officer of the Company for scientific advisory services. The agreement provides for annual payments of $30,000, payable $2,500 per month.   As of December 31, 2012, amounts owed to the shareholder were $2,500 and were included in accounts payable.
	The Company also entered into a consulting agreement with a shareholder to provide strategic and business development assistance. The agreement provides for annual payments of $60,000 payable $5,000 per month. At December 31, 2012, amounts owed to the shareholder for consulting fees were $30,000 and were included in accounts payable.  As of December 31, 2011, amounts owed to the shareholder for consulting fees were $59,861 and were included in accounts payable.  On March 2, 2012, the shareholder converted the amounts owed as of such date for accrued fees to 1,197,220 shares of common stock.
	Due to Shareholder
	A shareholder advanced the Company $10,000 which was due as of December 31, 2012 and 2011.   Such advance does not bear interest and is due upon demand.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2012
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 10.	Segment Information
	In 2011 and 2012, the Company distinguished its two main operating segments by entity and the types of products they sell. GeneLink develops and manufactures genetically customized supplements and skin care products for sale in a variety of market channels. GeneWize was the marketing subsidiary which sells GeneLink’s products in the multi-level direct selling channel. As noted in Note 11, GeneWize was sold on February 10, 2012.  Subsequent to the sale of GeneWize, the company only operates in one reporting segment. The following table sets forth the net revenues, operating expenses and net losses of our segments for the years ended December 31, 2012 and 2011
			GeneLink			GeneWize*			Inter-Segment			Total
	Year Ended December 31, 2012
	Revenue		$	1,785,346		$	520,098		$	(169,302	)	$	2,136,142
	Less:  Intersegment revenue			( 169,302	)					169,302			-
	Revenue from external customers		$	1,616,044		$	520,098			-		$	2,136,142
	Net Loss		$	(2,975,518	)	$	(76,229	)		-		$	(3,051,747	)
	Depreciation and amortization		$	169,048		$	5,945			-		$	174,993
	Capital expenditures		$	241,966			-			-		$	241,966
	Segment Assets at December 31, 2012		$	1,454,801			-			-		$	1,454,801
	Year Ended December 31, 2011
	Revenue		$	1,879,441		$	4,661,886		$	(1,856,749	)	$	4,684,577
	Less:  Intersegment revenue			( 1,856,749	)				$	1,856,749			-
	Revenue from external customers		$	22,692		$	4,661,886			-		$	4,684,577
	Net Loss		$	(3,153,389	)	$	(676,807	)		-		$	(3,830,196	)
	Depreciation and amortization		$	51,104		$	83,673			-		$	134,777
	Capital expenditures		$	41,327			-			-		$	41,327
	Segment Assets at December 31, 2011		$	2,304,929		$	585,692			-		$	2,779,665
	*2012 amounts are for the period from January 1, 2012 through the sale on February 10, 2012

Sale_of_Subsidiary_and_Licensi

Sale of Subsidiary and Licensing Agreements	12 Months Ended
	Dec. 31, 2012
Business Combinations [Abstract]	'
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	'
	Note 11:	Sale of Subsidiary and Licensing Agreements
	On October 13, 2011, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Capsalus Corp. (“Capsalus”), pursuant to which the Company agreed to sell 100% of the stock of its wholly-owned subsidiary, GeneWize Life Sciences, Inc. (“GeneWize”).  The Stock Purchase Agreement provided for a purchase price of $500,000 payable at the closing, plus an earn-out of between $1.5 million and $4.5 million, subject to the performance of GeneWize after the closing. The earn-out amount is calculated as the greater of $25,000 per month or 10% to 15% of GeneWize monthly gross revenues, payable monthly through April, 2017.  The effective date of the closing was February 10, 2012 which was the date final documents were completed following approval of the transaction by the shareholders of GeneLink.  Due to continuing involvement with GeneWize subsequent to the sale, this transaction was not accounted for as a discontinued operation.
	GeneLink recorded a gain on sale of subsidiary as of February 10, 2012.  Consideration for the sale included the $500,000 cash received from Capsalus and an additional $39,272 for working capital.  Additional consideration included the earn-out amount which was valued at $164,358, the Company’s estimate of net present value of probable cash collections under the agreement.   The total consideration of $703,630 was offset by net liabilities and related costs of sale resulting in a gain on sale of $669,054.
	The table below provides a detail of the calculation of the Gain on Sale.
	Consideration Paid
	Cash paid at closing			500,000
	Working Capital settlement items			39,272
	Present Value of earn-out deemed collectible			164,358
	Total Consideration			703,630
	Carrying Amount of Assets less Liabilities of GeneWize
	Assets			498,148
	Liabilities			(793,815	)
	Total Carrying Amount			(295,667	)
	Transaction Expenses			240,243
	Net Gain on Sale Recorded in Q1			759,054
	Working Capital settlement items noted in Q2			90,000
	Gain on sale for 2012			669,054
	The assets and liabilities sold were accounted for at our carrying amounts for such items on the February 10, 2012 date of sale.  Assets consisted of Cash $90,000, Accounts Receivable $254,000, Prepaid expenses $101,000, and fixed assets of $53,000.  Liabilities consisted of debt of $374,000, trade payables of $324,000, accrued wages and commissions of $40,000 and accrued sales taxes and other expenses of $55,000.   GeneLink, GeneWize and Capsalus also entered into an Interim Management Agreement dated October 13, 2011, pursuant to which Capsalus managed the operation of GeneWize until the closing date of February 10, 2012.  Pursuant to the Interim Management Agreement, Capsalus was responsible for all expenses and received all revenues of GeneWize from October 1, 2011 through the date of closing.   Capsalus advanced $204,500 to GeneWize prior to December 31, 2011 to fund operations which was recorded as “Advances from Purchaser” on the accompanying balance sheet at December 31, 2011 and an additional $75,000 was advanced to GeneWize by Capsalus prior to the closing of the sale of GeneWize.  This amount was assumed by GeneWize in February 2012 upon the closing of the sale of GeneWize.
	On October 13, 2011, GeneLink entered into a License and Distribution Agreement (the “LDA”) with Gene Elite LLC (“Gene Elite”) which expires in 2017 with successive five-year renewal options provided Gene Elite meets sales and performance criteria.  Pursuant to the LDA, GeneLink granted Gene Elite the exclusive right to sell certain skin care and nutrition products in the direct sales, multi- level marketing (MLM) and athletic formula channels. Pursuant to the LDA, the Company received $1,500,000 in license fees, of which $1,000,000 (the “Up-front fee”) was received during 2011 and $500,000 was received on February 10, 2012, the closing date of the sale of GeneWize. The LDA provides for $750,000 of the Up-front fee as a Nonrefundable Advance Deposit which accrues interest at 4% per year and will be paid through product credits or issuance of common stock at market price, at the discretion of Gene Elite. The remaining $750,000 of the license fees was recorded as “Deferred Revenue - License Fees” on the accompanying balance sheet, which will be recognized over the term of the LDA beginning on February 10, 2012.    As of December 31, 2012 the remaining balance in deferred revenue was $612,500 and $137,500 of the deferred revenue has been amortized into revenue during 2012.
	In connection with the LDA, GeneLink and Gene Elite entered into a Warrant Purchase Agreement dated October 13, 2011 pursuant to which GeneLink granted Gene Elite warrants to purchase (i) 6,000,000 shares of common stock of GeneLink at an exercise price of $0.10 per share and (ii) 2,000,000 shares of common stock of GeneLink at an exercise price of $0.45 per share (collectively, the “non-performance warrants”). In addition, and, subject to certain performance requirements being satisfied, Gene Elite was granted warrants to purchase 6,000,000 shares of common stock of GeneLink at an exercise price of $0.20 per share (the “performance warrants”).   The 8,000,000 shares underlying the non-performance warrants, valued at $460,000 at issue date, are accounted for as “Prepaid Sales Incentives” on the accompanying balance sheet and will be amortized over the life of the licensing agreement.  As of December 31, 2012, $383,330  of  the prepaid sales incentive remained on the balance sheet as an asset and $76,670  was amortized into expense during 2012.
	The non-performance warrants were valued using a Binomial Lattice Option Valuation Technique (“Binomial”) and the following assumptions:
	Fair market value of asset		$	0.06
	Exercise price		$	0.10 - .0.45
	Expected life			5.0 Years
	Equivalent volatility			164	%
	Expected dividend yield			0	%
	Risk-free rate			4.5	%
	The issuance date of the performance warrants was the date of closing, February 10, 2012, and management currently does not expect the performance warrants to be earned.
	On February 10, 2012, GeneLink, Gene Elite and GeneWize entered into a sub-licensing and distribution agreement (SLDA) which grants GeneWize the exclusive rights contained in the LDA to market and sell certain skin care and nutrition products in the direct sales, multi- level marketing (MLM) and athletic formula channels.  The term of the SLDA is concurrent with the term of the LDA including the successive renewal options granted under the LDA.
	Through December 31, 2012, Capsalus has paid $165,900 of the earn-out amount.  Capsalus has failed to pay any earn-out due subsequent to June 30, 2012.  The Company is in discussions with Capsalus regarding this receivable.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2012
Loss Contingency [Abstract]	'
Contingencies Disclosure [Text Block]	'
	Note 12.	Contingencies
	In March 2011, the Company received a Civil Investigative Demand (“CID”) consisting of interrogatories and a request to produce documents from the FTC as part of its investigation into unnamed persons engaged directly or indirectly in the advertising or marketing of dietary supplements, foods, drugs, devices, or any other product or service intended to provide a health benefit or to affect the structure or function of the body. The Company expended significant resources in 2011 and into 2012 in an attempt to comply with this request.
	During 2012, the staff of the FTC (the “staff”) investigated the Company for potential violations of Sections 5 and 12 of the Federal Trade Commission Act, 15 U.S.C. Sections 45 and 52, in connection with the advertising, marketing and sale of its DNA Assessments and genetically customized nutritional supplements and skin repair serum products. The Company strongly believes its advertising and marketing are lawful and appropriate.
	Following additional discussions with the staff, on October 26, 2012, in order to resolve this matter, the Company entered into a proposed consent decree with the Federal Trade Commission with regard to the FTC’s investigation. The proposed order is subject to approval by the full Commission.
	The resolution of this matter may involve limitations on GeneLink’s activities, including but not limited to restrictions on the Company’s marketing claims and practices and the institution of monitoring obligations. These restrictions are also anticipated to apply to the marketing claims and practices of GeneLink’s marketing partners and distributors. The pending consent agreement does not include any fine and/or economic redress.
	In September 2009, the Company brought action against two prior law firms in New Jersey Superior Court, alleging that their failure to timely provide legal services and make or authorize required filings caused the Company to lose valuable Japanese and U.S. patent rights. In March 2010, the Company voluntarily dismissed one of the law firms from the action. In August 2010, the remaining law firm filed a counterclaim for alleged unpaid legal fees owed to it by the Company. The defendant attempted to remove the matter to U.S. District Court, but in it was remanded back to the New Jersey Superior Court. The defendant appealed the remand decision, but in 2012 the Federal Circuit dismissed the defendants appeal. In July 2012 the parties have agreed to mutually dismiss all claims against each other with prejudice.
	In the fourth quarter of 2012, we switched our provider of genetic testing laboratory services.  Our former provider of genetic testing laboratory services claims that we owe it approximately $150,000 under our arrangement with such company due to the alleged failure to meet certain minimum volume requirements.  We believe that we have valid defenses to these claims and do not owe our former laboratory such amounts.
	In November 2012, we were sued in the Circuit Court for the 11th Judicial Circuit in and for Miami – Dade County, Florida by a former consultant, alleging breach of contract and unjust enrichment.  In January 2013, we filed a motion to dismiss the complaint.  The complaint that was filed does not state an amount that the former consultant is seeking from us.  We believe that this amount is less than $25,000.

Going_Concern_and_Managements_

Going Concern and Management's Plans	12 Months Ended
	Dec. 31, 2012
Going Concern and Management Plans [Abstract]	'
Going Concern and Management Plans [Text Block]	'
	Note 13.	Going Concern and Management’s Plans
	The opinions of the Company’s independent registered public accounting firm on the audited financial statements as of and for the years ended December 31, 2012 and 2011 contain an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.
	The Company has a working capital deficit of $1,066,784, has incurred recurring operating losses since inception including a loss of $3.0 million in 2012 and had an accumulated deficit at December 31, 2012 of $27,612,062.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	To execute the Company's growth plans, it may need to seek additional funding through public or private financings, including debt or equity financings, and through other means, including collaborations and license agreements. Additional financing may not be available when needed, or if available, the Company may not be able to obtain financing on favorable terms. The Company's ability to continue as a going concern is dependent upon the achievement of its marketing plans to enhance sales and its ability to raise capital.  Management continues to work with existing market partners as well as pursuing additional distribution opportunities.  Management also believes it has the opportunities before it to increase sales which will provide a foundation for raising additional capital. The Company’s financial statements have been prepared on the basis that it is a going concern, which assumes continuity of operations and the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments that might result if the Company was forced to discontinue its operations.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2012
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 14.	Subsequent Events
	On January 28, 2013 GeneLink accepted the resignation of Susan Hunt as Interim Chief Financial Officer of the Company effective as of February 8, 2013. An interim Chief Financial Officer, Dr. Bernard L. Kasten, Jr., M.D. was appointed effective February 8, 2013.
	In November 2012, we were sued in the Circuit Court for the 11th Judicial Circuit in and for Miami – Dade County, Florida by a former consultant, alleging breach of contract and unjust enrichment.  In January 2013, we filed a motion to dismiss the complaint.  The complaint that was filed does not state an amount that the former consultant is seeking from us.  Although we believe that this amount is less than $25,000, we are unable at this time to determine the amount alleged to be owed by us to the former consultant.  On March 14, 2013, the Court granted GeneLink’s Motion to Dismiss or in the Alternative a More Definite Statement. No additional amount has been accrued as of December 31, 2012 related to this suit.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2012
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of consolidation:
	The consolidated financial statements include the accounts of GeneLink, Inc. and its wholly-owned Subsidiaries.  All significant intercompany accounts and transactions have been eliminated in the consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates:
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and cash equivalents:
	Highly liquid instruments purchased with a maturity of three months or less are considered to be cash equivalents.  At times, cash and cash equivalents may exceed federally insured limits.  The Company has not experienced any losses on such accounts. All non-interest bearing cash balances were fully insured at December 31, 2012 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and the Company's non-interest bearing cash balances may again exceed federally insured limits. The Company had $381,277 of interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2011 and no excess of interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2012.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable:
	Trade accounts receivable primarily represent amounts due from distributors of our products.  The company performs credit evaluations of each customer on an ongoing basis and generally does not require collateral or charge interest or fees on balances.  As of December 31, 2012 and 2011, the Company has not recorded an allowance for doubtful accounts as management determined all amounts are collectible.
Inventory, Policy [Policy Text Block]	'
	Inventory:
	Inventory is valued at the lower of cost (using the first-in, first-out method) or market.  Inventory consists primarily of raw materials for the custom nutritional and skincare products sold by the Company.  Cost is determined on a specific identification basis. Work in process  and finished goods inventory are insignificant in relation to the raw material inventory since production process is short and goods are manufactured to order and shipped shortly after completion.  The cost of finished goods inventory includes the cost of materials, third-party contract manufacturing and overhead. In the event that the Company identifies excess, obsolete or unsalable inventory, its value is written down to net realizable value.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and equipment:
	Property and equipment are stated at cost.  Expenditures for maintenance and repairs are charged against operations.  Renewals and betterments that materially extend the life of the assets are capitalized.  Depreciation is computed using the straight-line method over the estimated useful lives or the lesser of the expected life or term of the lease as to leasehold improvements as noted below:
	Office furniture and equipment	3 - 5 years
	Equipment	3 - 5 years
	Leasehold improvements	5 years
	Software	3 - 5 years
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'
	Intangible Assets:
	Intangible assets include costs incurred to apply and obtain patents for its products. Patents are amortized upon approval by regulatory authorities over the estimated useful life of the asset, generally fifteen years on a straight-line basis.
Deferred Charges, Policy [Policy Text Block]	'
	Deferred Loan Costs:
	Loan acquisition costs are amortized over the term of the debt using the effective interest method.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Long lived assets:
	The Company reviews its long-lived assets and certain identifiable intangibles for impairment whenever events or changes indicate that the carrying amount of an asset may not be recoverable.  An impairment loss would be recognized when estimated future cash flows expected to result from the use of an asset and its eventual disposition is less than its carrying amount.  The Company recorded $65,517 of impairment loss from abandonment of patents in the year ended December 31, 2012 and had not identified any such impairment losses during the year ended December 31, 2011.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition:
	The Company recognizes revenues from the sales of products upon shipment.  Revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred and title and risk of loss have transferred to the customer, the sales price is determinable and collectability is reasonably assured.
	For direct sales to consumers by the Company’s subsidiary, GeneWize, prior to its sale in 2012, revenue was reduced for refunds on certain products during the trial period which is the first 60 days after the initial order is shipped. The Company recorded a reserve for refunds based on historical refunds provided to customers which is recorded as a reduction of revenue and is included in accrued expenses on the accompanying balance sheet.   The Company received advance payments from these consumer sales which was recorded as deferred revenue until shipment occurs.
	Prepaid sales incentives and deferred revenue-license fees represent prepaid fees that are deferred and recognized over the term of the underlying agreement with licensees.
	The Company recognizes revenue from licensing agreements as earned, which is generally when products are shipped from distributors, over the term of the agreement.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development:
	Research and development costs are expensed as incurred.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising
	The Company expenses advertising when incurred.  Advertising expense was $28,924 and $57,825 for the years ended December 31, 2012 and 2011, respectively.
Compensation Related Costs, Policy [Policy Text Block]	'
	Stock-Based Compensation:
	Stock-based compensation is recorded for recognition of the cost of employee or director services received in exchange for an award of equity instruments in the financial statements and is measured based on the grant date fair value of the award.  The stock-based compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (typically, the vesting period).
	The Company estimates the fair value of each option award issued under its stock option plans on the date of grant using a lattice option-pricing model that uses the following assumptions:
		a)	The Company estimates the volatility of its common stock at the date of grant based on the historical volatility of its common stock for a period commensurate with the expected life. These historical periods may exclude portions of time when unusual transactions occurred.
		b)	The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures.
		c)	For shares that vest contingent upon achievement of certain performance criteria, an estimate of the probability of achievement is applied in the estimate of fair value. If the goals are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed.
		d)	The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future.
		e)	The risk-free interest rate is based upon a treasury security with a maturity comparable to the contractual term of the options.
	In addition, the Company separates the grants into homogeneous groups and analyzes the assumptions for each group and computes the expense for each group utilizing these assumptions.
			Assumptions for Awards Granted in
			Years Ended December 31,
			2012			2011
	Expected volatility			180-182	%		144-203	%
	Risk-free interest rate			4.5	%		4.5-5.0	%
	Expected dividend yield			0	%		0	%
	Expected life in years			5.0-10.0			5.0 – 10.0
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings per share:
	Basic loss per share is calculated using the weighted average number of common shares outstanding for the period and diluted is computed using the weighted average number of common shares and dilutive common equivalent shares outstanding.  Given that the Company is in a net loss position, there is no difference between basic and diluted weighted average shares since the common stock equivalents would be antidilutive.
	The following common stock equivalents are excluded from the loss per share calculation as their effect would have been antidilutive:
			Year Ended December 31,
			2012			2011
	Options			21,980,833			19,631,833
	Warrants			24,248,042			22,552,458
	Debt conversion shares			16,794,583			15,544,583
	Debt conversion warrants			1,875,000			1,875,000
Income Tax, Policy [Policy Text Block]	'
	Income taxes:
	The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.
	The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2008 through December 31, 2012.
Derivatives, Reporting of Derivative Activity [Policy Text Block]	'
	Derivative Financial Instruments:
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and equity instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required to be accounted for separately from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results. An evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.
Beneficial Conversion and Warrant Valuation [Policy Text Block]	'
	Beneficial Conversion and Warrant Valuation:
	The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt instruments that have conversion features at fixed rates that are in-the-money when issued.  The Company also records the fair value of warrants issued in connection with debt instruments. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds to warrants, based on their relative fair value, and as a reduction to the carrying amount of the convertible instrument equal to the intrinsic value of the conversion feature. The discounts recorded in connection with the BCF and warrant valuation are recognized for convertible debt as interest expense over the term of the debt using the effective interest method.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments:
	The Company’s financial instruments are recorded at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. There are three levels of inputs that may be used to measure fair value:
		·	Level 1 – Valuation based on quoted market prices in active markets for identical assets and liabilities.
		·	Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.
		·	Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2012. The Company uses the market approach to measure fair value of its Level 1 financial assets.  The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
	The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s convertible notes payable approximate their carrying value based upon current rates available to the Company.
	In 2009, the Company issued Convertible Notes and warrants to a group of accredited investors (see Note 8). The Company engaged a third party to complete a valuation of the warrants issued to the placement agent and note holders and the conversion feature under the Convertible Notes which are recorded as debt costs and debt discounts on the accompanying balance sheets. The valuation was completed using Level 2 inputs.
	During 2011, the Company issued warrants in connection with a license and distribution agreement (see Note 11) and engaged a third party to complete a valuation of those warrants which were recorded as Prepaid Sales Incentive on the accompanying balance sheet. The valuation was completed using Level 2 inputs.
Other Business Risks [Policy Text Block]	'
	Industry Risk and Concentration:
	The business of marketing nutrition and skin care products is highly competitive and sensitive to the introduction of new products which may rapidly capture a significant share of the market. These market segments include numerous manufacturers, distributors, marketers, retailers and physicians that actively compete for the business of consumers both in the United States and abroad. In addition, the Company anticipates that it will be subject to increasing competition in the future from sellers that utilize electronic commerce. Many of these competitors have longer operating histories, significantly greater financial, technical, product development, marketing and sales resources, greater name recognition, larger established customer bases and better-developed distribution channels than does the Company.
	The Company’s present or future competitors may be able to develop products that are comparable or superior to those offered by the Company, adapt more quickly than the Company does to new technologies, evolving industry trends and standards or customer requirements, or devote greater resources to the development, promotion and sale of their products than does the Company. For example, if the Company’s competitors develop skin care or nutritional treatments that prove to be more effective than our products, demand for our products could be reduced. Accordingly, the Company may not be able to compete effectively in our markets and competition may intensify.  The Company is also subject to significant competition for the recruitment of distributors from other network marketing organizations, including those that market nutritional supplements and skin care products as well as other types of products.
	The Company’s ability to be competitive will depend, in significant part, on its success in recruiting and retaining market partners through the maintenance of an attractive product portfolio and other incentives. The Company cannot ensure that its programs for recruitment and retention of partners  will be successful, and if they are not, the Company’s financial condition and operating results would be harmed.
	The Company sells its products through a limited number of distributors. Certain of these distributors, together with entities under their common control, each individually accounted for greater than 10% of total revenues and greater than 10% of accounts receivable as follows: Revenues for 2012 and accounts receivable as of December 31, 2012 from GeneWize, our former subsidiary were $1,476,000 and $77,811, respectively which accounted for 69% of our net sales for the year and 100% of our outstanding accounts receivable at year end. No other customers were more than 10% of sales and revenues generated outside the United States were less than 10% of total revenues for all years presented.
	The Company relies entirely on a limited number of third parties to supply raw materials, manufacture our products and perform laboratory tests on the Company’s behalf. In the event any of the Company’s third party suppliers, manufacturers or laboratories was to become unable or unwilling to continue to provide the Company with services and products in required volumes and at suitable quality levels, the Company would be required to identify and obtain acceptable replacement sources.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent accounting pronouncements
	In July 2012, the Financial Accounting Standards Board completed an accounting standards update entitled "ASU 2012-02, Intangibles - Goodwill and Other" that revises the requirements around how entities test indefinite-lived intangible assets, other than goodwill, for impairment. The guidance will allow entities to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. If entities determine, on the basis of qualitative factors, that the fair value of the indefinite-lived intangible asset is more likely than not greater than the carrying amount, a quantitative calculation would not be needed. The Company will adopt this standard in the first quarter of 2013 and does not expect the adoption of this standard to have an impact on its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2012
Accounting Policies [Abstract]	'
Schedule Of Property Plant and Equipment Useful Life [Table Text Block]	'
	Depreciation is computed using the straight-line method over the estimated useful lives or the lesser of the expected life or term of the lease as to leasehold improvements as noted below:
	Office furniture and equipment	3 - 5 years
	Equipment	3 - 5 years
	Leasehold improvements	5 years
	Software	3 - 5 years
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	In addition, the Company separates the grants into homogeneous groups and analyzes the assumptions for each group and computes the expense for each group utilizing these assumptions.
			Assumptions for Awards Granted in
			Years Ended December 31,
			2012			2011
	Expected volatility			180-182	%		144-203	%
	Risk-free interest rate			4.5	%		4.5-5.0	%
	Expected dividend yield			0	%		0	%
	Expected life in years			5.0-10.0			5.0 – 10.0
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following common stock equivalents are excluded from the loss per share calculation as their effect would have been antidilutive:
			Year Ended December 31,
			2012			2011
	Options			21,980,833			19,631,833
	Warrants			24,248,042			22,552,458
	Debt conversion shares			16,794,583			15,544,583
	Debt conversion warrants			1,875,000			1,875,000

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following:
		December 31,
		2012			2011
	Office furniture and equipment	$	4,135		$	85,651
	Machinery  & equipment		288,105			301,091
	Leasehold improvements		169,629			6,781
	Software		21,946			343,902
	Less accumulated depreciation		(226,046	)		(569,613	)
		$	257,769		$	167,812

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets consisted of the following:
		December 31,
		2012			2011
	Patents approved	$	77,574		$	70,556
	Patents pending		115,237			188,298
	Less accumulated amortization		(137,906	)		(23,267	)
		$	54,905		$	235,587
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	The future estimated amortization expense on patents and other intangible assets that will be charged to operations as of December 31, 2012 is as follows:
	Year ending
	December 31,
	2013	$	11,901
	2014		9,190
	2015		8,235
	2016		7,697
	2017		2,758
	Thereafter		15,124
		$	54,905

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Components of deferred tax assets (liabilities) are as follows:
		December 31,
		2012			2011
	Stock compensation	$	856,000		$	713,900
	Other components		148,000			137,200
	Net operating loss carryforwards		6,778,000			7,826,700
			7,782,000			8,677,800
	Valuation Allowance		(7,782,000	)		( 8,677,800	)
		$	-		$	-

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'
Schedule Of Share-Based Compensation, Stock Warrants, Activity [Table Text Block]	'
	Warrants outstanding as of December 31, 2012 are as follows:
	Warrant Description	Shares			Exercise		Expiration
					Price		Date
	Placement Agent  Fees		12,490,542		$	0.03-$0.15		2013-2017
	Partner performance warrants		400,000		$	0.05		2017
	License fees		8,000,000		$	0.10-$0.45		2016
	Private  Placement warrants		3,357,500		$	0.10-$0.15		2013-2016
	Total warrants		24,248,042
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	The following table summarizes the activity of the stock warrants outstanding for the years ended December 31, 2011 and 2012:
		Shares Under
		Warrant
	Balance, January 1, 2011		13,087,958
	Warrants Issued		11,104,500
	Warrants Exercised		(1,640,000	)
	Warrants Expired		-
	Balance, December 31, 2011		22,552,458
	Warrants Issued		5,441,667
	Warrants Exercised		(100,000	)
	Warrants Expired		(3,646,083	)
	Balance, December 31, 2012		24,248,042
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes activity of the stock options outstanding for the years ended December 31, 2012 and 2011:
		Shares Under			Weighted
		Option			Average
					Exercise Price
	Balance,  January 1, 2011		15,682,833		$	0.13
	Options granted at market		4,900,000			0.09
	Options exercised		(1,000	)		0.07
	Options forfeited or expired		(950,000	)		0.08
	Balance, December 31, 2011		19,631,833			0.12
	Options granted at market		3,060,000			0.04
	Options forfeited or expired		(711,000	)		0.08
	Balance, December 31, 2012		21,980,833		$	0.11
Schedule of Nonvested Share Activity [Table Text Block]	'
	A summary of the non-vested shares as of December 31, 2012 and changes during the year ending December 31, 2012 and 2011 is presented below:
		Non-Vested Shares			Weighted Average Grant-Date Fair Value
	Non-vested at January 1, 2011		5,820,333		$	0.19
	Granted		4,900,000			0.08
	Vested		(3,412,000	)		0.16
	Non-vested at January 1, 2012		7,308,333		$	0.14
	Granted		3,060,000			0.04
	Vested		(4,118,125	)		0.07
	Cancelled		(250,000	)		0.08
	Non-vested at December 31, 2012		6,000,208		$	0.07

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2012
Leases [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum lease payments with terms in excess of one year as of December 31, 2012 are as follows:
	Year ending
	December 31,
	2013	$	202,404
	2014		208,476
	2015		214,730
	2016		221,172
	2017		93,287
		$	940,069

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2012
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The following table sets forth the net revenues, operating expenses and net losses of our segments for the years ended December 31, 2012 and 2011
		GeneLink			GeneWize*			Inter-Segment			Total
	Year Ended December 31, 2012
	Revenue	$	1,785,346		$	520,098		$	(169,302	)	$	2,136,142
	Less:  Intersegment revenue		( 169,302	)					169,302			-
	Revenue from external customers	$	1,616,044		$	520,098			-		$	2,136,142
	Net Loss	$	(2,975,518	)	$	(76,229	)		-		$	(3,051,747	)
	Depreciation and amortization	$	169,048		$	5,945			-		$	174,993
	Capital expenditures	$	241,966			-			-		$	241,966
	Segment Assets at December 31, 2012	$	1,454,801			-			-		$	1,454,801
	Year Ended December 31, 2011
	Revenue	$	1,879,441		$	4,661,886		$	(1,856,749	)	$	4,684,577
	Less:  Intersegment revenue		( 1,856,749	)				$	1,856,749			-
	Revenue from external customers	$	22,692		$	4,661,886			-		$	4,684,577
	Net Loss	$	(3,153,389	)	$	(676,807	)		-		$	(3,830,196	)
	Depreciation and amortization	$	51,104		$	83,673			-		$	134,777
	Capital expenditures	$	41,327			-			-		$	41,327
	Segment Assets at December 31, 2011	$	2,304,929		$	585,692			-		$	2,779,665
	*2012 amounts are for the period from January 1, 2012 through the sale on February 10, 2012

Sale_of_Subsidiary_and_Licensi1

Sale of Subsidiary and Licensing Agreements (Tables)	12 Months Ended
	Dec. 31, 2012
Business Combinations [Abstract]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	The table below provides a detail of the calculation of the Gain on Sale.
	Consideration Paid
	Cash paid at closing	500,000
	Working Capital settlement items	39,272
	Present Value of earn-out deemed collectible	164,358
	Total Consideration	703,630
	Carrying Amount of Assets less Liabilities of GeneWize
	Assets	498,148
	Liabilities	(793,815	)
	Total Carrying Amount	(295,667	)
	Transaction Expenses	240,243
	Net Gain on Sale Recorded in Q1	759,054
	Working Capital settlement items noted in Q2	90,000
	Gain on sale for 2012	669,054
Schedule Of Non Performance Warrants [Table Text Block]	'
	The table below provides a detail of the calculation of the Gain on Sale.
	Consideration Paid
	Cash paid at closing	500,000
	Working Capital settlement items	39,272
	Present Value of earn-out deemed collectible	164,358
	Total Consideration	703,630
	Carrying Amount of Assets less Liabilities of GeneWize
	Assets	498,148
	Liabilities	(793,815	)
	Total Carrying Amount	(295,667	)
	Transaction Expenses	240,243
	Net Gain on Sale Recorded in Q1	759,054
	Working Capital settlement items noted in Q2	90,000
	Gain on sale for 2012	669,054

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2012
Office Equipment [Member]	'
Property, Plant and Equipment, Estimated Useful Lives	'3 - 5 years
Equipment [Member]	'
Property, Plant and Equipment, Estimated Useful Lives	'3 - 5 years
Leasehold Improvements [Member]	'
Property, Plant and Equipment, Estimated Useful Lives	'5B B years
Software [Member]	'
Property, Plant and Equipment, Estimated Useful Lives	'3 b 5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Risk-free interest rate	4.50%	'
Expected dividend yield	0.00%	0.00%
Maximum [Member]	'	'
Expected volatility	182.00%	203.00%
Risk-free interest rate	'	5.00%
Expected life in years	'10 years	'10 years
Minimum [Member]	'	'
Expected volatility	180.00%	144.00%
Risk-free interest rate	'	4.50%
Expected life in years	'5 years	'5 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Stock Options [Member]	'	'
Common stock equivalents are excluded from computation of loss per share	21,980,833	19,631,833
Warrant [Member]	'	'
Common stock equivalents are excluded from computation of loss per share	24,248,042	22,552,458
Convertible Debt Securities [Member]	'	'
Common stock equivalents are excluded from computation of loss per share	16,794,583	15,544,583
Convertible Debt Securities, Warrants [Member]	'	'
Common stock equivalents are excluded from computation of loss per share	1,875,000	1,875,000

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Insurance Coverage Revert Per Depositer	$250,000	'
Advertising Expense	28,924	57,825
Gain (Loss) On Abandonment Of Patents	-65,517	0
Revenue Refunded Period Description	'60	'
Revenues	2,136,142	4,684,577
Accounts Receivable	77,966	235,458
Gene Wize [Member]	'	'
Revenues	1,476,000	'
Accounts Receivable	77,811	'
Entity-Wide Revenue, Major Customer, Percentage	69.00%	'
Entity Wide Accounts Receivable Major Customer Percentage	100.00%	'
Interest-Bearing Deposits [Member]	'	'
Interest-bearing Deposit Liabilities	'	$381,277

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Office furniture and equipment	$4,135	$85,651
Machinery & equipment	288,105	301,091
Leasehold improvements	169,629	6,781
Software	21,946	343,902
Less accumulated depreciation	-226,046	-569,613
Property, Plant and Equipment, Net	$257,769	$167,812

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Depreciation	$98,258	$129,707
Cost of Goods Sold, Depreciation	$38,003	'

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Patents approved	$77,574	$70,556
Patents pending	115,237	188,298
Less accumulated amortization	-137,906	-23,267
Intangible Assets, Net (Excluding Goodwill)	$54,905	$235,587

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 31, 2012
Year ending December 31,	'
2013	$11,901
2014	9,190
2015	8,235
2016	7,697
2017	2,758
Thereafter	15,124
Finite-Lived Intangible Assets, Net	$54,905

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Amortization of Deferred Charges	$114,738	$5,070
Accelerated Amortization, Intangible Assets	106,000	'
Impairment of Intangible Assets, Finite-lived	$65,517	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Stock compensation	$856,000	$713,900
Other components	148,000	137,200
Net operating loss carryforwards	6,778,000	7,826,700
Deferred Tax Assets, Gross	7,882,000	8,677,800
Valuation Allowance	-7,882,000	-8,677,800
Deferred Tax Assets, Net	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012
Operating Loss Carryforwards	$17,958,000
Operating Loss Carryforwards, Expiration Dates	'expire in various amounts between 2014 and 2031.
Valuation Allowance, Deferred Tax Asset, Change in Amount	($895,800)

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Placement Agent Fees [Member]

Placement Agent Fees [Member]

Placement Agent Fees [Member]

Partner Performance Warrants [Member]

License Fees [Member]

License Fees [Member]

License Fees [Member]

Private Placement Warrants [Member]

Private Placement Warrants [Member]

Private Placement Warrants [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Warrant Description, Shares

24,248,042

22,552,458

13,087,958

12,490,542

'

'

400,000

8,000,000

'

'

3,357,500

'

'

Warrant Description, Exercise Price

'

'

'

'

$0.03

$0.15

$0.05

'

$0.10

$0.45

'

$0.10

$0.15

Warrant Description, Expiration Date

'

'

'

'2013-2017

'

'

'2017

'2016

'

'

'2013-2016

'

'

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Shares Under Option, Beginning Period	19,631,833	15,682,833
Shares Under Option, Options granted at market	3,060,000	4,900,000
Shares Under Option, Options exercised	'	-1,000
Shares Under Option, Options forfeited or expired	-711,000	-950,000
Shares Under Option, Ending Period	21,980,833	19,631,833
Weighted Average Exercise Price, Beginning Period	$0.12	$0.13
Weighted Average Exercise Price, Options granted at market	$0.04	$0.09
Weighted Average Exercise Price, Options exercised	'	$0.07
Weighted Average Exercise Price, Options forfeited or expired	$0.08	$0.08
Weighted Average Exercise Price, Ending Period	$0.11	$0.12

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Non-Vested Shares, Beginning Period	7,308,333	5,820,333
Non-Vested Shares, Granted	3,060,000	4,900,000
Non-Vested Shares, Vested	-4,118,125	-3,412,000
Non-Vested Shares, Cancelled	-250,000	'
Non-Vested Shares, Ending Period	6,000,208	7,308,333
Weighted Average Grant-Date Fair Value, Beginning Period	$0.14	$0.19
Weighted Average Grant-Date Fair Value, Granted	$0.04	$0.08
Weighted Average Grant-Date Fair Value, Vested	$0.07	$0.16
Weighted Average Grant-Date Fair Value, Cancelled	$0.08	'
Weighted Average Grant-Date Fair Value, Ending Period	$0.07	$0.14

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Balance, Begining	22,552,458	13,087,958
Warrants Issued	5,441,667	11,104,500
Warrants Exercised	-100,000	-1,640,000
Warrants Expired	-3,646,083	0
Balance, Ending	24,248,042	22,552,458

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2007

Dec. 31, 2012

Dec. 31, 2009

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Joel Guerin [Member]

Common Stock [Member]

Common Stock [Member]

First Equity Capital Securities Inc [Member]

First Equity Capital Securities Inc [Member]

Plan 2007 [Member]

Plan 2007 [Member]

Plan 2009 [Member]

Plan 2009 [Member]

Plan 2011 [Member]

Plan 2011 [Member]

Board Designated Options [Member]

Board Designated Options [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock Exercise Price (in dollars per share)

'

'

'

'

$0.03

$0.05

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

'

'

$1,504,000

$2,299,320

'

'

'

'

'

'

'

'

'

'

Payments of Stock Issuance Costs

'

'

'

'

71,000

139,180

'

'

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price (in dollars per share)

'

'

'

'

'

'

$0.03

$0.05

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

6,000,000

'

6,000,000

'

10,000,000

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'10 years

'

'10 years

'

'10 years

'

'

'

Shares Under Option, Balance

21,980,833

19,631,833

15,682,833

'

'

'

'

'

'

'

'

'

'

'

4,945,833

4,945,833

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for services (in shares)

'

'

'

'

1,497,226

300,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number

15,980,625

'

'

'

'

'

'

'

'

5,050,000

'

3,906,250

'

2,674,375

4,350,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

$0.11

$0.12

$0.13

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'6 years 5 months 8 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

292,525

356,925

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock pursuant to private placement offerings, net of offering costs (in shares)

'

'

'

'

52,500,000

48,770,000

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for services

74,862

22,745

'

'

14,973

3,000

'

'

'

'

'

'

'

'

'

'

Share price (in dollars per share)

'

$0.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Warrants Exercised

100,000

1,640,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options and warrants (in shares)

'

'

'

'

28,160

501,300

'

'

'

'

'

'

'

'

'

'

Minimum Option Price Percentage Based On Market Value

'

'

'

'

'

'

'

'

100.00%

'

100.00%

'

100.00%

'

'

'

Share Based Compensation Arrangement Share Based Payment Award Average Fair Value Of Options

$0.04

$0.09

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Future Compensation Cost Estimated In Next Twelve Months

234,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued To Purchase Common Stock

'

'

'

'

'

'

5,041,667

3,104,500

'

'

'

'

'

'

'

'

Total Future Compensation Cost Estimated Within Two Years

126,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Future Compensation Cost Estimated Within Three Years

$52,950

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued

5,441,667

11,104,500

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

Non Performance Warrants Number (in shares)

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Leases_Details

Leases (Details) (USD $)	Dec. 31, 2012
Year ending December 31,	'
2013	$202,404
2014	208,476
2015	214,730
2016	221,172
2017	93,287
Operating Leases, Future Minimum Payments Due	$940,069

Leases_Details_Textual

Leases (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Operating Leases, Rent Expense	$135,680	$64,900

Convertible_Notes_Payable_Rela1

Convertible Notes Payable - Related Parties (Details Textual) (USD $)	12 Months Ended				22 Months Ended	25 Months Ended		1 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Feb. 26, 2011	Feb. 28, 2009	Feb. 28, 2009	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
			Convertible Notes 2009 [Member]	Convertible Notes 2009 [Member]	Convertible Notes 2009 [Member]	Convertible Notes 2009 [Member]	Convertible Notes 2009 [Member]	Note Warrants 2009 [Member]	Note Warrants 2009 [Member]	Note Warrants 2009 [Member]	Placement Agent [Member]
Convertible Notes Payable	'	'	$1,250,000	$1,250,000	$1,250,000	'	$1,250,000	'	'	'	'
Warrants Issued To Purchase Common Stock	'	'	'	'	'	'	'	1,875,000	'	'	1,265,000
Debt Instrument, Interest Rate During Period	'	'	'	'	10.00%	8.00%	'	'	'	'	'
Debt Instrument, Convertible, Terms of Conversion Feature	'	'	'A mandatory conversion of the Convertible Notes will occur if the closing price of the Company's Common Stock is at least $0.50 per share for 30 consecutive trading days. The conversion price on the Convertible Notes is $0.10 per share, subject to adjustment under standard anti-dilution provisions, as defined in the agreements.	'	'	'	'	'	'	'	'
Investment Warrants, Exercise Price (in dollars per share)	'	'	'	'	'	'	'	'	$0.11	'	$0.11
Investment Warrants Expiration Date	'	'	'	'	'	'	'	'	26-Feb-14	'	'
Convertible Notes Payable Fair Value	'	'	1,328,325	'	'	'	'	'	'	'	'
Warrants Fair Value	'	'	'	'	'	'	'	'	204,750	'	132,800
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term	'	'	'	'	'	'	'	'	'5 years	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	'	'	'	'	'	'	'	'	138.00%	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	'	'	'	'	'	'	'	'	163.00%	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	4.50%	'	'	'	'	'	'	'	4.98%	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	'	'	'	'	'	'	0.00%	'	'
Proceeds From Convertible Notes Discounted For Warrants	'	'	'	'	'	'	'	'	166,395	'	'
Interest Expense, Debt	'	'	45,554	41,565	'	'	'	'	37,536	34,248	'
Total Fair Value Convertible Notes Payable	'	'	1,083,605	'	'	'	'	'	'	'	'
Debt Instrument, Convertible, Beneficial Conversion Feature	'	'	406,395	'	'	'	'	'	'	'	'
Debt Instrument, Convertible, Beneficial Conversion Feature Amortization	'	'	86,997	79,379	'	'	'	'	'	'	'
Payments of Debt Issuance Costs	'	'	'	'	'	'	'	'	'	'	80,000
Debt Issuance Cost	'	'	'	'	'	'	'	'	'	'	80,000
Unamortized Debt Issuance Expense	'	'	58,703	104,256	58,703	'	'	'	'	'	'
Debt Instrument, Unamortized Discount	'	'	$160,453	$284,985	$160,453	'	'	'	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Due To Officers Or Stockholders, Current	$10,000	$10,000
Scientific Advisory Services [Member]	'	'
Annual Payment Of Consulting Fees	30,000	'
Consulting Fees Payable Monthly	2,500	'
Due To Officers Or Stockholders, Current	2,500	'
Strategic and Business Development Assistance [Member]	'	'
Annual Payment Of Consulting Fees	60,000	'
Consulting Fees Payable Monthly	5,000	'
Due To Officers Or Stockholders, Current	30,000	59,861
Stock Issued During Period Conversion Of Accrued Stipend	1,197,220	'
Placement Agent [Member]	'	'
Equity Method Investment, Ownership Percentage	5.00%	'
Placement Agent Fees	$71,000	$78,720
Warrants Issued To Purchase Common Stock1	5,041,667	3,104,500
Investment Warrants, Exercise Price1 (in dollars per share)	$0.03	$0.05

Segment_Information_Details

Segment Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2012		Dec. 31, 2011
Revenue	$2,136,142		$4,684,577
Less: Intersegment revenue	0		0
Revenue from external customers	2,136,142		4,684,577
Net Loss	-3,051,747		-3,830,196
Depreciation and amortization	174,993		134,777
Capital expenditures	241,966		41,355
Segment Assets	1,454,801		2,779,665
Gene Link [Member]	'		'
Revenue	1,785,346		1,879,441
Less: Intersegment revenue	-169,302		-1,856,749
Revenue from external customers	1,616,044		22,692
Net Loss	-2,975,518		-3,153,389
Depreciation and amortization	169,048		51,104
Capital expenditures	241,966		41,355
Segment Assets	1,454,801		2,304,929
Gene Wize [Member]	'		'
Revenue	520,098	[1]	4,661,886	[1]
Revenue from external customers	520,098	[1]	4,661,886	[1]
Net Loss	-76,229	[1]	-676,807	[1]
Depreciation and amortization	5,945	[1]	83,673	[1]
Capital expenditures	0	[1]	0	[1]
Segment Assets	0	[1]	585,692	[1]
Inter-Segment [Member]	'		'
Revenue	-169,302		-1,856,749
Less: Intersegment revenue	169,302		1,856,749
Revenue from external customers	0		0
Net Loss	0		0
Depreciation and amortization	0		0
Capital expenditures	0		0
Segment Assets	$0		$0
[1]	2012 amounts are for the period from January 1, 2012 through the sale on February 10, 2012

Sale_of_Subsidiary_and_Licensi2

Sale of Subsidiary and Licensing Agreements (Details) (Non Performance Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2012
Fair market value of asset (in dollars per share)	$0.06
Expected life	'5 years
Equivalent volatility	164.00%
Expected dividend yield	0.00%
Risk-free rate	4.50%
Minimum [Member]	'
Exercise price (in dollars per share)	$0.10
Maximum [Member]	'
Exercise price (in dollars per share)	$0.45

Sale_of_Subsidiary_and_Licensi3

Sale of Subsidiary and Licensing Agreements (Details Textual) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

Oct. 31, 2011

Mar. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Feb. 10, 2012

Dec. 31, 2011

Oct. 31, 2011

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2012

Mar. 31, 2012

Feb. 10, 2012

Dec. 31, 2011

Oct. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Up Front Fee [Member]

Gene Elite [Member]

Gene Elite [Member]

Capsalus [Member]

Capsalus [Member]

Gene Wize [Member]

Gene Wize [Member]

Gene Wize [Member]

Gene Wize [Member]

Gene Link [Member]

Minimum [Member]

Maximum [Member]

Warrant Issued One [Member]

Warrant Issued Two [Member]

Prepaid Sales Incentives

'

'

$291,330

$383,333

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Price Paid

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Earnings Based On Performance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

4,500,000

Consideration Paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid at closing

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

Working capital settlement items

'

'

'

'

'

'

'

'

'

'

90,000

39,272

'

'

'

'

'

Present Value of earn-out deemed collectible

'

'

'

'

'

'

'

'

'

'

'

164,358

'

'

'

'

'

Total Consideration

'

'

'

'

'

'

'

'

'

'

'

703,630

'

'

'

'

'

Carrying Amount of Assets less Liabilities of GeneWize

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets

'

'

'

'

'

'

'

'

'

'

'

498,148

'

'

'

'

'

Liabilities

'

'

'

'

'

'

'

'

'

'

'

-793,815

'

'

'

'

'

Total Carrying Amount

'

'

'

'

'

'

'

'

'

'

'

-295,667

'

'

'

'

'

Transaction Expenses

'

'

'

'

'

'

'

'

'

'

'

240,243

'

'

'

'

'

Gain on sale of subsidiary

'

'

669,054

0

'

'

'

'

'

'

669,054

759,054

'

'

'

'

'

Assets of Disposal Group, Including Discontinued Operation [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash

'

'

'

'

'

'

'

'

'

'

'

'

90,000

'

'

'

'

Accounts Receivable

'

'

'

'

'

'

'

'

'

'

'

'

254,000

'

'

'

'

Prepaid expenses

'

'

'

'

'

'

'

'

'

'

'

'

101,000

'

'

'

'

Fixed assets

'

'

'

'

'

'

'

'

'

'

'

'

53,000

'

'

'

'

Liabilities of Disposal Group, Including Discontinued Operation [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt

'

'

'

'

'

'

'

'

'

'

'

'

374,000

'

'

'

'

Trade payables

'

'

'

'

'

'

'

'

'

'

'

'

324,000

'

'

'

'

Accrued wages and commissions

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

Accrued sales taxes and other expenses

'

'

'

'

'

'

'

'

'

'

'

'

55,000

'

'

'

'

Earnings Calculated

'

'greater of $25,000 per month or 10% to 15% of GeneWize monthly gross revenues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances from purchaser of subsidiary

'

'

0

204,500

'

'

'

'

'

204,500

'

'

'

75,000

'

'

'

License and Services Revenue

'

500,000

'

1,500,000

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

Non-refundable advance deposit for licensing agreement

'

'

725,043

750,000

750,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest Rate On Nonrefundable Advance Deposit

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

'

'

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Purchased From Warrants Granted (in shares)

'

'

'

'

'

'

6,000,000

6,000,000

'

'

'

'

'

'

2,000,000

'

'

Earn Out Receivable

'

'

'

'

'

'

'

'

165,900

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price (in dollars per share)

'

'

'

'

'

'

$0.10

$0.20

'

'

'

'

'

'

$0.45

'

'

Non Performance Warrants Number (in shares)

'

'

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Non Performance Warrants Value

460,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Revenue Total

'

'

612,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Revenue, Revenue Recognized

'

'

137,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of prepaid sales incentives

'

'

$76,670

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingencies_Details_Textual

Contingencies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012
Loss Contingency, Damages Sought, Value	$150,000
Subsequent Event [Member]	'
Loss Contingency, Range of Possible Loss, Maximum	$25,000

Going_Concern_and_Managements_1

Going Concern and Management's Plans (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Working Capital Deficit	$1,066,784	'
Net Income (Loss) Attributable To Parent	3,051,747	3,830,196
Retained Earnings (Accumulated Deficit)	$27,612,062	$24,560,315

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	Dec. 31, 2012
Subsequent Event [Member]	'
Loss Contingency, Range of Possible Loss, Maximum	$25,000